Mesenchymal large cell lymphoma (ALCL) is a malignancy with high CD30 expression, accounting for approximately 2-3% of non-Hodgkin’s lymphomas. SGN-35 is a combination of an anti-CD30 antibody and a potential anti-microtubule protein drug, MMAE, that initiates the apoptotic program by selectively binding to CD30-positive cells and releasing MMAE. Professor A. Shustov from Seattle, USA, reported the results of a single-arm, multicenter phase II clinical study of the efficacy and safety of using SGN-35 for relapsed, refractory ALCL. Fifty-eight patients with relapsed, refractory ALCL were enrolled in the study, with a median age of 52 years and 72% of those with ALK(-). Patients were given SGN-35 1.8 mg/kg, intravenous drip, every 3 weeks for 16 cycles. The results showed an overall effective rate of 86%, of which 53% achieved complete remission. The median objective remission time has not yet been reached, with the current remission time ranging from 0.3 to 45.3 weeks. Treatment-related adverse effects were mainly peripheral sensory neuropathy, malignancy, malaise, diarrhea, and neutropenia. The high degree of efficacy of SGN-35 in treating patients with drug-resistant ALCL has never been seen in previous treatments for this type of lymphoma, and the adverse effects are tolerable. The drug has been filed with the State Drug Administration of China and is expected to enter clinical trials in China.